Known targets — ChEMBL curated mechanism
KCNA5KCND3KCNH2KCNJ3KCNJ5SCN5A
The experimentally established mechanism targets of Vernakalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 6/20 | 0.98 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vernakalant SCHEMBL2632638 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL2624885 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL411090 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL12203901 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL411046 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL670359 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL14390243 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL2624888 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL14390429 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL13097995 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CORREVIO CANADA CORP. (CA) | 2015-11-26 | — | — | US | disclosed |
| US-9115081-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-9115081-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2015-08-25 | — | — | US | disclosed |
| EP-1868598-B1 | A NEW DOSING REGIMEN FOR ION CHANNEL MODULATING COMPOUNDS FOR TREATING ACUTE ATRIAL FIBRILLATION IN A HUMAN | CARDIOME PHARMA CORP (CA) | 2014-04-23 | — | — | EP | disclosed |
| US-8692002-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2014-04-08 | — | — | US | disclosed |
| US-8692002-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2014-04-08 | — | — | US | disclosed |
| US-20130102791-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2013-04-25 | — | — | US | disclosed |
| US-20080171785-A1 | Dosing Regimens For Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080171785-A1 | Dosing Regimens For Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-7345087-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-7345087-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102791-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | KCNA5 3600/4885SCN5A 3852/4885KCNH2 1977/4885 |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885KCNH2 1/4885 |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885KCNH2 1/4885 |
| US-20080171785-A1 | Dosing Regimens For Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | KCNA5 59/4885SCN5A 39/4885KCNH2 21/4885 |
| US-20150336887-A1 | SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS | DDC, PAICS, CYP4F2 | KCNA5 3600/4885SCN5A 3852/4885KCNH2 1977/4885 |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885KCNH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.